Neuroscience News

Researchers at Stanford’s Knight Initiative for Brain Resilience merge spatial transcriptomics and AI to uncover how local cellular interactions drive brain aging and resilience

New research shows aging is not a uniform process. Parts of our bodies start aging earlier than others, right down to our organs and cells.

Fat-filled microglia may play a role in the damage caused by Alzheimer’s, especially for those who carry two copies a particular gene.

With Knight Initiative support, Stanford researchers uncover a biochemical “off-ramp” in ketosis, rewriting our understanding of how ketosis influences metabolism.

The Knight Initiative for Brain Resilience supports 14 high-risk, high-reward projects to advance brain health and resilience research, fostering bold research across various scientific disciplines.

This week on From Our Neurons to Yours, we talk with Stanford neurologist Mike Greicius about his critique of new amyloid-clearing Alzheimer's drugs, and his optimism for the next wave of therapies currently in development.

Study in mice, supported by the Knight Initiative, suggests that an experimental cancer drug boosted brain metabolism, restored memory, and improved Alzheimer's symptoms. This novel approach may offer a new way to treat Alzheimer's beyond targeting amyloid plaques.

The APOE4 genetic variant, carried by about 20% of people, significantly raises Alzheimer’s risk. But should we boost the gene’s potency or suppress it? A recent discovery by Knight Initiative affiliate, Mike Greicius, may provide the answers we need.

A team of neuroscientists at the Knight Initiative for Brain Resilience have zeroed in on a critical regulator of brain metabolism that may be over-activated in the brains of patients with Alzheimer’s disease.

Groundbreaking research supported by the Knight Initiative for Brain Resilience at Stanford’s Wu Tsai Neurosciences Institute deepens our understanding of how the amino acid taurine may help reduce appetite and prevent obesity.

The Knight Initiative's Year-End Symposium and Research Showcase featured a wide range of promising new approaches to understanding brain aging, resilience, and neurodegeneration.

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease, but which also carry safety risks according to Knight Initiative for Brain Resilience affiliate Mike Greicius and others.

Why do our brains get worse at learning as we get older, and what can we do about it? Institute affiliate Carla Shatz discusses our brain's capacity for change on this podcast episode.

Most Parkinson’s disease patients struggle with speech problems. New research by Stanford Medicine scientists uncovers the brain connections that could be essential to preserving speech.

This week on From Our Neurons to Yours, we talk with memory expert Anthony Wagner about the nature of memory and how to improve it.

Wu Tsai Neuro and Knight Initiative for Brain Resilience affiliate, Michael Greicius, and others share their expertise on the limitations of the Alzheimer's drug Leqembi.